Eli Lilly and Company (NYSE:LLY) EVP Anat Hakim Sells 5,000 Shares of Company Stock

by · The Markets Daily

Eli Lilly and Company (NYSE:LLY – Get Free Report) EVP Anat Hakim sold 5,000 shares of the company’s stock in a transaction that occurred on Monday, November 2nd. The shares were sold at an average price of $1,402.52, for a total value of $7,012,600.00. Following the transaction, the executive vice president directly owned 4,137 shares in the company, valued at approximately $5,802,225.24. This represents a 54.72% decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is available at this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.

Anat Hakim also recently made the following trade(s):

  • On Friday, August 7th, Anat Hakim sold 5,000 shares of Eli Lilly and Company stock. The stock was sold at an average price of $1,190.00, for a total value of $5,950,000.00.

Eli Lilly and Company Trading Down 0.2%

LLY traded down $2.31 during trading hours on Tuesday, reaching $1,408.68. 2,712,512 shares of the company’s stock traded hands, compared to its average volume of 2,947,000. The firm has a 50-day moving average price of $1,200.81 and a 200 day moving average price of $1,094.25. The firm has a market capitalization of $1.33 trillion, a PE ratio of 45.72, a PEG ratio of 1.73 and a beta of 0.40. The company has a quick ratio of 1.00, a current ratio of 1.35 and a debt-to-equity ratio of 1.41. Eli Lilly and Company has a 52-week low of $850.51 and a 52-week high of $1,449.68.

Eli Lilly and Company (NYSE:LLY – Get Free Report) last released its earnings results on Thursday, October 29th. The company reported $7.48 earnings per share for the quarter, topping the consensus estimate of $5.71 by $1.77. The business had revenue of $24.40 billion during the quarter, compared to the consensus estimate of $22.58 billion. Eli Lilly and Company had a return on equity of 97.83% and a net margin of 33.53%. The business’s revenue for the quarter was up 38.6% compared to the same quarter last year. During the same period last year, the company earned $7.02 earnings per share. As a group, sell-side analysts predict that Eli Lilly and Company will post 35.18 EPS for the current fiscal year.

Eli Lilly and Company Dividend Announcement

The business also recently announced a quarterly dividend, which will be paid on Thursday, December 10th. Stockholders of record on Friday, November 13th will be given a dividend of $1.73 per share. The ex-dividend date of this dividend is Friday, November 13th. This represents a $6.92 dividend on an annualized basis and a dividend yield of 0.5%. Eli Lilly and Company’s dividend payout ratio (DPR) is 22.46%.

Institutional Inflows and Outflows

Several institutional investors and hedge funds have recently added to or reduced their stakes in the business. Ethos Capital Management Inc. increased its stake in Eli Lilly and Company by 20.9% in the 3rd quarter. Ethos Capital Management Inc. now owns 2,068 shares of the company’s stock worth $2,392,000 after purchasing an additional 358 shares in the last quarter. Pictet Asset Management Holding SA raised its holdings in Eli Lilly and Company by 10.5% during the 3rd quarter. Pictet Asset Management Holding SA now owns 834,060 shares of the company’s stock worth $965,373,000 after buying an additional 79,075 shares during the period. Allen Investment Management LLC lifted its stake in Eli Lilly and Company by 3.1% during the third quarter. Allen Investment Management LLC now owns 8,877 shares of the company’s stock valued at $10,271,000 after buying an additional 264 shares in the last quarter. Formidable Asset Management LLC lifted its stake in Eli Lilly and Company by 12.6% during the third quarter. Formidable Asset Management LLC now owns 13,067 shares of the company’s stock valued at $15,673,000 after buying an additional 1,460 shares in the last quarter. Finally, Verus Capital Partners LLC boosted its holdings in shares of Eli Lilly and Company by 3.2% in the third quarter. Verus Capital Partners LLC now owns 1,389 shares of the company’s stock worth $1,607,000 after buying an additional 43 shares during the period. 82.53% of the stock is currently owned by hedge funds and other institutional investors.

Wall Street Analysts Forecast Growth

LLY has been the topic of several research analyst reports. Citigroup increased their price objective on Eli Lilly and Company from $1,600.00 to $1,650.00 and gave the stock a “buy” rating in a research note on Friday. The Goldman Sachs Group reiterated a “buy” rating and issued a $1,413.00 target price on shares of Eli Lilly and Company in a report on Tuesday, October 20th. Bank of America reissued a “buy” rating and set a $1,497.00 price target on shares of Eli Lilly and Company in a research report on Friday. Truist Financial restated a “buy” rating and set a $1,612.00 price target (up from $1,376.00) on shares of Eli Lilly and Company in a research note on Friday. Finally, Morgan Stanley lifted their price objective on Eli Lilly and Company from $1,430.00 to $1,596.00 and gave the company an “overweight” rating in a report on Friday. One investment analyst has rated the stock with a Strong Buy rating, twenty-four have given a Buy rating, three have given a Hold rating and one has given a Sell rating to the company. According to MarketBeat.com, the stock presently has a consensus rating of “Moderate Buy” and a consensus target price of $1,404.14.

Get Our Latest Report on Eli Lilly and Company

Key Headlines Impacting Eli Lilly and Company

Here are the key news stories impacting Eli Lilly and Company this week:

  • Positive Sentiment: Lilly’s third-quarter revenue of $24.4 billion and EPS of $7.48 topped analyst estimates. The company also raised its full-year revenue guidance to $91 billion–$92 billion, reinforcing expectations for continued growth. Article: Raised Guidance Altering The Investment Case For Eli Lilly Stock?
  • Positive Sentiment: Demand for Mounjaro and Zepbound remains a major growth driver. A report also highlighted Phase 3 results in which experimental retatrutide outperformed Ozempic 2 mg in a diabetes trial, potentially strengthening Lilly’s competitive position if further development succeeds. Article: Eli Lilly Just Gained 22% in a Month
  • Positive Sentiment: Analyst optimism adds support: Morgan Stanley raised its price target amid surging demand for Lilly’s weight-loss drugs, and Cantor Fitzgerald raised its target to $1,600 while maintaining an Overweight rating. Article: Unprecedented weight-loss drug craze pushing Lilly to near-record highs
  • Neutral Sentiment: Lilly continues to invest beyond obesity and diabetes, including in oncology and AI-supported Alzheimer’s research, but its broader pipeline has also seen candidates discontinued. The long-term payoff is uncertain. Article: Lilly’s R&D whirlwind
  • Negative Sentiment: Some coverage cautions that the shares’ sharp run-up leaves little room for disappointment. Lilly’s reliance on its leading GLP-1 products, signs of slower future revenue growth, and falling realized drug prices could weigh on the investment case. Article: Eli Lilly Jumped 6% After Earnings

Eli Lilly and Company Company Profile

(Get Free Report)

Eli Lilly and Company (NYSE: LLY) is a global pharmaceutical company that discovers, develops, manufactures and markets medicines for a range of medical conditions. Its major therapeutic areas include diabetes and obesity, oncology, immunology, neuroscience and cardiovascular health.

The company’s portfolio includes Mounjaro and Trulicity for diabetes, Zepbound for chronic weight management, Humalog insulin, Taltz for inflammatory diseases, Verzenio for certain breast cancers and Kisunla for early symptomatic Alzheimer’s disease.

Featured Stories